Tetrathiomolybdate (TM) a copper-lowering drug, has efficacy in Wilson's disease, cancer, disease of neovascularization, and potential efficacy in diseases of inflammation and/or fibrosis. In Wilson's disease TM has been developed for initial therapy, the first two to four months of treatment, to quickly and safely gain control of copper toxicity. TM is efficacious in cancer and other diseases of angiogenesis because it has antiangiogenic effects on a number of angiogenic cytokines and promoters. TM also inhibits fibrotic and inflammatory cytokines, and is effective in a number of animal models of inflammation and fibrosis.
展开▼
